【英語タイトル】Viral Vector Manufacturing Market Report: Trends, Forecast and Competitive Analysis to 2030
	・商品コード：LUCI79324SP239 ・発行会社（調査会社）：Lucintel ・発行日：2023年10月 ・ページ数：150 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後4営業日） ・調査対象地域：グローバル ・産業分野：医療・バイオ

Viral Vector Manufacturing Trends and Forecast

The future of the global viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets. The global viral vector manufacturing market is expected to reach an estimated $3.0 billion by 2030 with a CAGR of 18.7% from 2024 to 2030. The major drivers for this market are increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing, and technological advancements in viral vector manufacturing.

A more than 150-page report is developed to help in your business decisions.

Viral Vector Manufacturing by Segment

The study includes a forecast for the global viral vector manufacturing by type, workflow, application, end use, and region.

Viral Vector Manufacturing Market by Type [Shipment Analysis by Value from 2018 to 2030]:

Adenovirus
Retrovirus
Adeno-Associated Virus
Lentivirus
Plasmid DNA
Others
Viral Vector Manufacturing Market by Workflow [Shipment Analysis by Value from 2018 to 2030]:

Upstream Manufacturing
Downstream Manufacturing
Viral Vector Manufacturing Market by Application [Shipment Analysis by Value from 2018 to 2030]:

Cell & Gene Therapy
Vaccinology
Research & Other Applications
Viral Vector Manufacturing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

Pharmaceutical & Biopharmaceutical
Research Institutes
Others
Viral Vector Manufacturing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

North America
Europe
Asia Pacific
The Rest of the World
List of Viral Vector Manufacturing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies viral vector manufacturing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the viral vector manufacturing companies profiled in this report include-

Merck
Lonza
Fujifilm Diosynth Biotechnologies
Thermo Fisher Scientific
Cobra Biologics
Catalent
Wuxi Biologics
Takara Bio
Waisman Biomanufacturing
Genezen Laboratories
Viral Vector Manufacturing Market Insights

Lucintel forecasts that cell and gene therapy is expected to witness highest growth over the forecast period due to growing demand for cell and gene therapies for the treatment of a wide range of diseases, including cancer, rare diseases, and genetic disorders.

Within this market, pharmaceutical and biopharmaceutical will remain the largest segment due to the fact that these pharmaceutical and biopharmaceutical companies companies are developing and commercializing viral vector-based therapies for a wide range of diseases, including cancer, rare diseases, and infectious diseases.

North America is expected to witness highest growth over the forecast period due to increasing demand for viral vector-based therapies from the pharmaceutical and biotechnology industries in the region.

Features of the Global Viral Vector Manufacturing Market

Market Size Estimates: Viral vector manufacturing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Viral vector manufacturing market size by various segments, such as by type, workflow, application, end use, and region in terms of value ($B).

Regional Analysis: Viral vector manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, workflows, applications, end uses, and regions for the viral vector manufacturing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the viral vector manufacturing market.

Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q.1 What is the viral vector manufacturing market size?

Answer: The global viral vector manufacturing market is expected to reach an estimated $3.0 billion by 2030.

Q.2 What is the growth forecast for viral vector manufacturing market?

Answer: The global viral vector manufacturing market is expected to grow with a CAGR of 18.7% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the viral vector manufacturing market?

Answer: The major drivers for this market are increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing and technological advancements in viral vector manufacturing.

Q4. What are the major segments for viral vector manufacturing market?

Answer: The future of the viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets.

Q5. Who are the key viral vector manufacturing market companies?

Answer: Some of the key viral vector manufacturing companies are as follows:

Merck
Lonza
Fujifilm Diosynth Biotechnologies
Thermo Fisher Scientific
Cobra Biologics
Catalent
Wuxi Biologics
Takara Bio
Waisman Biomanufacturing
Genezen Laboratories
Q6. Which viral vector manufacturing market segment will be the largest in future?

Answer: Lucintel forecasts that cell and gene therapy is expected to witness highest growth over the forecast period due to growing demand for cell and gene therapies for the treatment of a wide range of diseases, including cancer, rare diseases, and genetic disorders.

Q7. In viral vector manufacturing market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to increasing demand for viral vector-based therapies from the pharmaceutical and biotechnology industries in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the viral vector manufacturing market by type (adenovirus, retrovirus, adeno-associated virus, lentivirus, plasmid DNA, and others), workflow (upstream manufacturing and downstream manufacturing), application (cell & gene therapy, vaccinology, and research & other applications), end use (pharmaceutical & biopharmaceutical, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?